Gebo Kelly A, Fleishman John A, Moore Richard D
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):609-16. doi: 10.1097/01.qai.0000171727.55553.78.
Rapid changes in HIV epidemiology and highly active antiretroviral therapy (HAART) may have resulted in recent changes in patterns of inpatient utilization.
To examine trends in inpatient diagnoses and mortality in HIV patients.
DESIGN/SETTING/PATIENTS: Serial cross-sectional analyses of HIV patients hospitalized in 1996, 1998, and 2000, using hospital discharge data from the Healthcare Costs and Utilization Project for 12 states. Each hospitalization was classified as an opportunistic illness, complication of injection drug use (IDU), liver-related complication, ischemic heart disease, cerebrovascular disease, non-Pneumocystis carinii pneumonia (PCP), diabetes, or chronic hepatitis C virus (HCV).
Number of hospital admissions, inpatient mortality.
We evaluated 316,963 admissions that occurred between 1996 and 2000, with an overall mortality of 7%. Hospitalizations for opportunistic infections significantly decreased from 40% to 27% of all HIV-related admissions. The overall proportion of IDU complications remained relatively stable (6%) each year. Hospitalizations increased for liver-related complications from 8% to 13% and for chronic HCV from 1% to 5% in this period. The number of hospitalizations for cerebrovascular disease and for ischemic heart disease was relatively negligible in all years. Overall, inpatient mortality decreased between 1996 and 2000. Relatively higher mortality was observed among African Americans, Hispanics, those with Medicaid, those with Medicare, and the uninsured, however. Opportunistic infections and liver-related complications were associated with greater inpatient mortality.
Results do not show a significant recent rise in HIV-related inpatient utilization. Admissions to treat opportunistic infections have declined precipitously, consistent with the effects of HAART. Although not dramatic, liver-related disease is an increasing cause of hospitalization in HIV+ patients.
HIV流行病学的快速变化以及高效抗逆转录病毒疗法(HAART)可能导致了近期住院利用模式的改变。
研究HIV患者住院诊断和死亡率的趋势。
设计/地点/患者:对1996年、1998年和2000年住院的HIV患者进行系列横断面分析,使用来自12个州医疗成本和利用项目的医院出院数据。每次住院被分类为机会性疾病、注射吸毒并发症(IDU)、肝脏相关并发症、缺血性心脏病、脑血管疾病、非卡氏肺孢子虫肺炎(PCP)、糖尿病或慢性丙型肝炎病毒(HCV)。
住院次数、住院死亡率。
我们评估了1996年至2000年间发生的316,963次住院,总体死亡率为7%。机会性感染的住院率从所有HIV相关住院的40%显著下降至27%。IDU并发症的总体比例每年相对稳定(6%)。在此期间,肝脏相关并发症的住院率从8%增至13%,慢性HCV的住院率从1%增至5%。脑血管疾病和缺血性心脏病的住院次数在所有年份相对较少。总体而言,1996年至2000年间住院死亡率下降。然而,非裔美国人、西班牙裔、有医疗补助者、有医疗保险者以及未参保者的死亡率相对较高。机会性感染和肝脏相关并发症与更高的住院死亡率相关。
结果未显示近期HIV相关住院利用有显著上升。治疗机会性感染的住院次数急剧下降,这与HAART的效果一致。尽管不显著,但肝脏相关疾病在HIV阳性患者中日益成为住院的原因。